Dual therapy with edoxaban plus a P2Y12 inhibitor is noninferior to triple therapy with a vitamin K antagonist (VKA) plus a P2Y12 inhibitor and aspirin for the risk of bleeding in patients with atrial fibrillation (AF) who had undergone percutaneous coronary intervention (PCI). These results from the ENTRUST-AF PCI trial were presented at the ESC Congress 2019. The trial was conducted in 18 countries and included 1,506 patients with AF who had had a successful PCI. Median time from PCI to randomization was 45.1 h. At 1 year, major or clinically relevant nonmajor bleeding events occurred in 17% and 20% of patients in the edoxaban and VKA groups, respectively (HR 0.83, 95% CI 0.65–1.05, P = 0.001 for noninferiority). Both groups had similar rates of the main efficacy outcome of ischaemic events.
References
Original article
Vranckx, P. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet https://doi.org/10.1016/S0140-6736(19)31872-0 (2019)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fernández-Ruiz, I. Edoxaban noninferior to VKA in AF after PCI. Nat Rev Cardiol 16, 646 (2019). https://doi.org/10.1038/s41569-019-0272-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41569-019-0272-4